
	August 28, 2008

Now Available:
Watch video podcasts of the 2008 EULAR press conferences

CME Opportunity:

Musculoskeletal Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.

Arthritis: Experts Urge More Attention to Vitamin D in Rheumatoid Arthritis
Vitamin D not only helps prevent steroid-induced osteoporosis in rheumatoid arthritis but might also help reduce falls and modulate disease activity...

Arthritis: Researchers Home in On Role of TNF in RA Bone Destruction
Tumor necrosis factor alpha (TNFα) decreases osteoblast numbers via an enzyme called Smad Ubiquitin Regulatory Factor 1 (SMURF1), which shuts down two proteins that would otherwise drive bone formation...

Arthritis: Pivotal Humira Trial Shows Durable Benefit in Juvenile Rheumatoid Arthritis
The pivotal trial of adalimumab (Humira) shows durable, safe efficacy for up to 2 years for children with polyarticular JRA and positions the TNF-inhibitor as the reasonable second-line drug to add if methotrexate does not provide sufficient disease control...

Consumer News: Vitamin D Deficiency May Lurk in Babies
Some infants are not getting enough vitamin D from breast milk, beginning a life plagued by vitamin D deficiency and bone health problems...

BioPharm Business: Mesoblast Reports Preclinical Study Shows Allogeneic Stem Cells in Ewes are Safe, Effective for Cervical Spine Fusion; Therapy May Receive Boost From US FDA's Recent Alert of Life-Threatening Complications Associated With rhBMP in Cervical Spine Fusions
Mesoblast is currently in phase II clinical trials for fusion of the lumbar spine and, based on these new results, will extend its market opportunity to cover the entire spectrum of spinal fusion. Subject to FDA approval, Mesoblast's therapy will eliminate the need for autograft...